John Perrett

524 total citations
10 papers, 424 citations indexed

About

John Perrett is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, John Perrett has authored 10 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 2 papers in Pharmacology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in John Perrett's work include Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers), Neonatal Respiratory Health Research (3 papers) and Respiratory Support and Mechanisms (3 papers). John Perrett is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers), Neonatal Respiratory Health Research (3 papers) and Respiratory Support and Mechanisms (3 papers). John Perrett collaborates with scholars based in United Kingdom, Sweden and Denmark. John Perrett's co-authors include Kulasiri A. Gunawardena, Kristina Forsman‐Semb, Neil Entwistle, Robert A. Stockley, Noel Snell, Anthony De Soyza, Claus Vogelmeier, Christopher D. O’Brien, Joanna Marks-Kończalik and J.S. Elborn and has published in prestigious journals such as Blood, European Respiratory Journal and British Journal of Clinical Pharmacology.

In The Last Decade

John Perrett

10 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Perrett United Kingdom 8 223 123 71 65 63 10 424
Yoichiro Ogama Japan 10 106 0.5× 116 0.9× 18 0.3× 190 2.9× 110 1.7× 16 609
Masafumi Nishino Japan 18 245 1.1× 46 0.4× 17 0.2× 64 1.0× 97 1.5× 59 862
Eric Mensier France 9 117 0.5× 28 0.2× 20 0.3× 94 1.4× 32 0.5× 13 351
Andrew P. Beelen United States 12 115 0.5× 25 0.2× 24 0.3× 161 2.5× 235 3.7× 35 553
Yannick Renaud Canada 7 38 0.2× 110 0.9× 196 2.8× 59 0.9× 34 0.5× 8 440
Dion Chen United States 8 46 0.2× 95 0.8× 62 0.9× 52 0.8× 35 0.6× 9 357
J. F. Costello United Kingdom 11 187 0.8× 27 0.2× 167 2.4× 64 1.0× 53 0.8× 14 396
F Bonnaud France 11 160 0.7× 20 0.2× 89 1.3× 69 1.1× 98 1.6× 53 399
Loretta Fala United States 14 61 0.3× 56 0.5× 49 0.7× 117 1.8× 47 0.7× 24 392
Tomoji Nishioka Japan 13 60 0.3× 27 0.2× 21 0.3× 87 1.3× 103 1.6× 23 418

Countries citing papers authored by John Perrett

Since Specialization
Citations

This map shows the geographic impact of John Perrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Perrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Perrett more than expected).

Fields of papers citing papers by John Perrett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Perrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Perrett. The network helps show where John Perrett may publish in the future.

Co-authorship network of co-authors of John Perrett

This figure shows the co-authorship network connecting the top 25 collaborators of John Perrett. A scholar is included among the top collaborators of John Perrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Perrett. John Perrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Gunawardena, Kulasiri A., et al.. (2013). Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD. International Journal of Clinical Pharmacology and Therapeutics. 51(4). 288–304. 15 indexed citations
2.
Stockley, Robert A., Anthony De Soyza, Kulasiri A. Gunawardena, et al.. (2013). Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respiratory Medicine. 107(4). 524–533. 148 indexed citations
3.
Vogelmeier, Claus, et al.. (2012). A Randomised, Placebo-Controlled, Dose-Finding Study Of AZD9668, An Oral Inhibitor of Neutrophil Elastase, in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium. COPD Journal of Chronic Obstructive Pulmonary Disease. 9(2). 111–120. 76 indexed citations
4.
Elborn, J.S., John Perrett, Kristina Forsman‐Semb, et al.. (2012). Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. European Respiratory Journal. 40(4). 969–976. 68 indexed citations
5.
Vogelmeier, Claus, et al.. (2012). A Randomised, Placebo-Controlled, Dose-Finding Study Of AZD9668, An Oral Inhibitor of Neutrophil Elastase, in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium. COPD Journal of Chronic Obstructive Pulmonary Disease. 1930885945–1930885945. 2 indexed citations
6.
Elborn, J.S., John Perrett, Kristina Forsman‐Semb, et al.. (2011). Effect Of The Oral Neutrophil Elastase Inhibitor, AZD9668, In Patients With Cystic Fibrosis. A6122–A6122. 4 indexed citations
7.
Laursen, L. C., et al.. (2003). The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation.. PubMed. 97 Suppl A. S23–33. 20 indexed citations
8.
Blakey, Graham, et al.. (2003). Pharmacokinetic and pharmacodynamic assessment of a five‐probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. British Journal of Clinical Pharmacology. 57(2). 162–169. 58 indexed citations
9.
10.
Jarvis, Gavin E., Robert G. Humphries, Ian P. Kirk, et al.. (1999). The P-2t antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel.. Blood. 94. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoichiro Ogama Breakdown of academic impact, for papers by Masafumi Nishino Breakdown of academic impact, for papers by Eric Mensier Breakdown of academic impact, for papers by Andrew P. Beelen Breakdown of academic impact, for papers by Yannick Renaud Breakdown of academic impact, for papers by Dion Chen Breakdown of academic impact, for papers by J. F. Costello Breakdown of academic impact, for papers by F Bonnaud Breakdown of academic impact, for papers by Loretta Fala Breakdown of academic impact, for papers by Tomoji Nishioka
Rankless by CCL
2026